Genesray Biotechnology (01548): Legend released multiple research results at the 2026 American Society of Clinical Oncology Annual Meeting.

The Zhitong Finance and Economics App reports that Kingsway Biotechnology (01548) has announced that its joint venture company, Legend Biotech Limited (Legend), whose shares are listed on the Nasdaq Global Selection Market in the form of American Depositary Shares, submitted a 6-K form to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York time) (before the Hong Kong trading session on May 22, 2026), announcing the presentation of multiple research results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. One of the highlights of the rapid oral presentation will focus on the Phase 1 preliminary data of LB2102, an investigational CAR-T therapy targeting DLL3 for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). In addition, new data on CARVYKTI (cilta-cel, Sicatuzumab govitecan-hziy) will also be disclosed.